Revance Therapeutics reported $-52391000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Aerie Pharmaceuticals AERI:US $ -16.59M 15.45M
ALKERMES ALKS:US $ -15.07M 7.68M
Bristol Myers Squibb BMY:US $ 5780M 8M
Cara Therapeutics CARA:US $ -4409000 23.44M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
Horizon Pharma HZNP:US $ 244.43M 47.12M
JAZZ PHA JAZZ:US $ 282.55M 15.29M
Johnson & Johnson JNJ:US $ 8036M 1273M
Neurocrine Biosciences NBIX:US $ 58.6M 52.2M
Pacira Pharmaceuticals PCRX:US $ 34.04M 7.72M
Revance Therapeutics RVNC:US $ -52.39M 4.45M
Supernus Pharmaceuticals SUPN:US $ 31.99M 8.66M
Teva Pharmaceutical Industries TEVA:US $ 1092M 20M